No connection

Search Results

ABBV vs NOTV

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
NOTV
Inotiv, Inc.
BEARISH
Price
$0.24
Market Cap
$8.4M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ABBV
163.63
NOTV
--
Forward P/E
ABBV
15.42
NOTV
-4.9
P/B Ratio
ABBV
-146.66
NOTV
0.08
P/S Ratio
ABBV
6.5
NOTV
0.02
EV/EBITDA
ABBV
15.27
NOTV
26.68

Profitability

Gross Margin
ABBV
71.46%
NOTV
23.49%
Operating Margin
ABBV
35.5%
NOTV
-13.36%
Profit Margin
ABBV
4.0%
NOTV
-13.5%
ROE
ABBV
137.96%
NOTV
-49.76%
ROA
ABBV
9.59%
NOTV
-3.14%

Growth

Revenue Growth
ABBV
9.1%
NOTV
0.8%
Earnings Growth
ABBV
-88.7%
NOTV
--

Financial Health

Debt/Equity
ABBV
--
NOTV
4.37
Current Ratio
ABBV
0.72
NOTV
0.3
Quick Ratio
ABBV
0.47
NOTV
0.17

Dividends

Dividend Yield
ABBV
3.05%
NOTV
--
Payout Ratio
ABBV
490.15%
NOTV
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
NOTV BEARISH

NOTV exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is facing a liquidity crisis with a Current Ratio of 0.30 and a Quick Ratio of 0.17, suggesting it cannot meet its short-term obligations. High leverage (Debt/Equity of 4.37) combined with stagnant revenue growth (0.80%) and consistent earnings misses creates a high risk of insolvency. The catastrophic 5-year price decline of 98.8% and bearish insider activity further confirm a negative outlook.

Strengths
Positive Gross Margin (23.49%)
Extremely low Price-to-Sales ratio (0.02)
Extremely low Price-to-Book ratio (0.08)
Risks
Severe liquidity risk (Current Ratio 0.30)
Excessive leverage (Debt/Equity 4.37)
Consistent failure to meet earnings estimates (0/4 beats)

Compare Another Pair

ABBV vs NOTV: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Inotiv, Inc. (NOTV) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile